ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[EVA1A overexpression improves non-alcoholic fatty liver disease in mice by regulating lipid metabolism and promoting lipophagy].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo investigate the role of transmembrane protein EVA1A in liver lipid metabolism and development of non-alcoholic fatty liver disease (NAFLD).
methodsEight-week-old male ob/ob mice were randomized into control group injected with AAV null vector
resultsThe mouse livers in AAV-Eva1a group and LV-EVA1A-transfected cells showed significantly increased expression levels of EVA1A mRNA and protein. The liver weight and coefficient and lipid deposition of the mice with AAV-Eva1a injection and triglyceride (TG) content in LV-EVA1A-transfected cells were significantly decreased. The mice in AAV-Eva1a group showed significantly reduced serum total cholesterol, LDL-C, and HDL-C levels and hepatic TG levels with lowered serum levels of ALT, AST, IL-6 and TNF‑α. In both mouse livers in AAV-Eva1a group and LV-EVA1A-transfected HepG2 cells, acetyl-CoA carboxylase, fatty acid transport protein, and diacylglycerol acyltransferase expressions were all significantly decreased and adipose triglyceride lipase increased. Hepatic lipophagy, autophagosome numbers and LC3-II and ATG5 expressions were enhanced and p62 expression was lowered in the mice in AAV-Eva1a group and LV-EVA1A-transfected cells.
conclusionsEVA1A overexpression alleviates fatty liver and inflammation in ob/ob mice by regulating lipid metabolism-related genes and enhancing lipophagy to promote clearance of accumulated hepatic lipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.